Clinical trials: Placebo Response
Rheumatoid Arthritis
GLPG0259 in Methotrexate-refractory Rheumatoid Arthritis
Part A: 30 patients suffering from active rheumatoid arthritis despite continued treatment with methotrexate will receive once daily two capsules containing either GLPG0259 (25 mg/capsule) or matching placebo, for 12 weeks.
- Trial name
- NCT01211249
- Testing
- GLPG0259 oral capsule, GLPG0259 (Part B)
- Where
- 32 sites in Belgium, Netherlands and 3 more
- Volunteers
- 30 people
- Sponsor
- Lakefront Biotherapeutics NV
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
- Trial name
- NCT03755713
- Testing
- ASP0892
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Influenza
Trial to Evaluate the Immune Response to OPV When Administered Concomitantly With CAIV-T to Healthy Children.
Phase III trial to evaluate the immune response to oral poliovirus vaccine (OPV) when administered concomitantly with CAIV-T to healthy children.
- Trial name
- NCT00192426
- Testing
- CAIV-T
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Partial Epilepsy
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
This is a multicenter, double-blind, randomized, placebo-controlled dose response study, with an 8-week prospective baseline and an 18 week double-blind treatment period (including a 6-week titration phase and 12 week maintenance…
- Trial name
- NCT01866111
- Testing
- YKP3089
- Where
- 67 sites in United States, Australia and 13 more
- Volunteers
- 437 people
- Sponsor
- SK Life Science, Inc.
Anemia
Treatment of Anemia in Diabetic Subjects With CKD
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline…
- Trial name
- NCT00240734
- Testing
- Epoetin alfa
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
To evaluate the dose-response relationship of AVE0010 administered once daily and twice daily with chronic dosing in metformin-treated subjects with type 2 diabetes
- Trial name
- NCT00299871
- Testing
- LIXISENATIDE (AVE0010)
- Where
- 7 sites in United States, Brazil and 5 more
- Volunteers
- 542 people
- Sponsor
- Sanofi
Rheumatoid Arthritis (RA)
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function.
- Trial name
- NCT04888585
- Testing
- ABBV-154
- Where
- 220 sites in United States, Australia and 19 more
- Volunteers
- 473 people
- Sponsor
- AbbVie
Idiopathic Parkinson's Disease
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
The purpose of this study is to determine the safety, efficacy and pharmacokinetics following administration of CVT-301 in treatment of "off" episodes in Parkinson's Disease patients.
- Trial name
- NCT01617135
- Testing
- CVT-301, Sinemet (carbidopa/levodopa)
- Where
- 7 sites in Israel, Serbia and 1 more
- Volunteers
- 25 people
- Sponsor
- Acorda Therapeutics
Attention Deficit Disorder With Hyperactivity
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00556959
- Testing
- high dose clonidine HCl sustained release, low dose clonidine HCl sustained release
- Where
- 13 sites in United States
- Volunteers
- 236 people
- Sponsor
- Addrenex Pharmaceuticals, Inc.
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Healthy Subject, Immunity
The Effect of the Consumption of 4 Botanical Extracts on Immunity in Healthy Adults (B-4-Immune)
This study will evaluate the capacity of botanical extracts to modulate immune mechanisms compared to a placebo group in healthy volunteers.
- Trial name
- B-4-Immune (NCT05117385)
- Testing
- Botanical extract
- Where
- France
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Asthma
Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects
This is a randomized, placebo-controlled, 2-period crossover, escalating repeat dose study, aiming to investigate whether higher potency of different inhaled corticosteroid confers an improvement in the topical efficacy to…
- Trial name
- NCT02991859
- Testing
- Fluticasone furoate (FF) Dry Powder Inhaler, Fluticasone propionate (FP) Dry Powder Inhaler, Budesonide (BUD) Turbuhaler
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 56 people
- Sponsor
- GlaxoSmithKline
Hypertension
Hemodynamic Effects of Aliskiren Compared to Captopril on the Kidney in Healthy Volunteers on a Low- and High- Sodium Diet
This study will measure the effects of different doses of aliskiren on kidney blood flow and function in healthy adults and determine how salt intake affects the response to aliskiren.
- Trial name
- NCT00518765
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novartis
Systemic Lupus Erythematosus
A Phase II Study of M2951 in SLE
M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study was to assess the Safety and Efficacy of M2951 in participants with Systemic Lupus Erythematosus…
- Trial name
- NCT02975336
- Testing
- M2951
- Where
- 157 sites in United States, Argentina and 17 more
- Volunteers
- 469 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Hot Flushes
E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)
This dose-finding study is being conducted to select the daily oral dose of estetrol (E4) for the treatment of vasomotor symptoms (VMS) in post-menopausal women.
- Trial name
- NCT02834312
- Testing
- Estetrol
- Where
- Belgium
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Donesta Bioscience
Type 2 Diabetes Mellitus
Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)
The purpose of this study is to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.
- Trial name
- NCT00673465
- Testing
- SCH 497079, Metformin
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00504270
- Testing
- RG3421 120mg, RG3421 20mg
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).
- Trial name
- NCT00002322
- Testing
- Atevirdine mesylate, Zidovudine
- Where
- 12 sites in United States
- Sponsor
- Pharmacia and Upjohn